# REGENERX BIOPHARMACEUTICALS INC

REGENERX BIOPHARMACEUTICALS INC is a company headquartered in Rockville, MD, United States.

## Company overview

- **Legal name:** REGENERX BIOPHARMACEUTICALS INC
- **Former names in filing history:** ALPHA 1 BIOMEDICALS INC (1995-12-28 to 2001-05-11); ALPHA 1 BIOMEDICALS INC /DE/ (1994-03-09 to 1995-02-07)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Rockville, MD, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0000707511

## About

REGENERX BIOPHARMACEUTICALS INC is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0000707511, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2023-04-11, it reported annual revenue of USD 76,761; net income of USD -1,727,455; total assets of USD 382,177 for the fiscal period ended 2022-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2022 (period ended 2022-12-31)

- **Revenue:** $76,761 (USD 76,761)
- **Net income:** -$1.7M (USD -1,727,455)
- **Total assets:** $382,177 (USD 382,177)
- **Cash and equivalents:** $290,890 (USD 290,890)
- **Operating cash flow:** -$940,718 (USD -940,718)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $76,761 (USD 76,761)
- **Net income:** -$1.6M (USD -1,597,755)
- **Total assets:** $1.3M (USD 1,284,965)
- **Cash and equivalents:** $1.2M (USD 1,231,608)
- **Operating cash flow:** -$990,296 (USD -990,296)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $76,761 (USD 76,761)
- **Net income:** -$1.5M (USD -1,523,368)
- **Total assets:** $551,788 (USD 551,788)
- **Cash and equivalents:** $427,898 (USD 427,898)
- **Operating cash flow:** -$1.0M (USD -1,006,929)

### FY2019 (period ended 2019-12-31)

- **Revenue:** $76,762 (USD 76,762)
- **Net income:** -$1.4M (USD -1,404,247)
- **Total assets:** $711,760 (USD 711,760)
- **Cash and equivalents:** $639,916 (USD 639,916)
- **Operating cash flow:** -$1.1M (USD -1,137,970)

## Recent SEC filings

- Form 8-K — filed 2023-08-07 — period 2023-08-03 — FORM 8-K
- Form DEF 14A — filed 2023-07-11 — period 2023-07-11 — DEF 14A
- Form 8-K — filed 2023-07-10 — period 2023-05-09 — FORM 8-K
- Form 8-K — filed 2023-06-21 — period 2023-06-13 — FORM 8-K
- Form 10-Q — filed 2023-05-15 — period 2023-03-31 — 10-Q
- Form 10-K — filed 2023-04-11 — period 2022-12-31 — 10-K
- Form 10-Q — filed 2022-11-14 — period 2022-09-30 — 10-Q
- Form 10-Q — filed 2022-08-12 — period 2022-06-30 — 10-Q
- Form 10-Q — filed 2022-05-16 — period 2022-03-31 — 10-Q
- Form 10-K — filed 2022-03-30 — period 2021-12-31 — FORM 10-K
- Form 10-Q — filed 2021-11-15 — period 2021-09-30 — FORM 10-Q
- Form 8-K — filed 2021-11-15 — period 2021-11-10 — FORM 8-K

---

Updated: 2026-10-23T20:09:28Z

Canonical page: https://altss.com/profile/regenerx-biopharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology